Skip to content

Psilocybin: all studies

Page 35 of 439: studies 341 to 350 of 4,389, newest first. Back to the psilocybin overview

Research

Review of: "Psilocybin in Alcohol Use Disorder Maintains Abstinence Efficacy: A Scoping Review"

February 1, 2026 Carlton J Spotswood

Things to consider: .In the intro: "The so-called magic mushrooms from which psychedelics are extracted were traditionally absorbed by South-American peoples." This is clunky and I suspect it is due to translation errors; consider changing it. .In the intro: "In 1998, Dr. Heffter nally discovered a psychedelic active substance and named it mescaline." This was rst published in 1897, not 1998....

The effect of psilocin on neurotransmitters release in the claustrum and on rat behavior.

Pharmacological Reports February 1, 2026 Zuzanna Kościuk, Izabela Szpręgiel, Agnieszka Bysiek et al. 2 citations

The claustrum, a subcortical structure densely expressing 5-hydroxytryptamine 2 A (5-HT2A) receptors, has been implicated in sensory integration, emotional regulation, salience, and attention. Despite its hypothesized involvement in the effects of serotonergic psychedelics, the neurochemical impact of these substances on claustral neurotransmission remains unexplored. This study aimed to...

Psilocybin and Bipolar Depression: Promise and Prudence.

CNS Drugs February 1, 2026 Matheus G Marques, Liliana Patarroyo-Rodriguez, Balwinder Singh

Bipolar disorder affects approximately 40 million individuals worldwide, with depression being the most prominent phase of the illness. Owing to limited treatment options, bipolar depression remains a major public health concern, often causing significant functional impairment and increased suicide risk. Current therapies frequently lack rapid effectiveness, highlighting the need for novel...

The Use of Psilocybin in the Treatment of Depressive Disorders: A Narrative Review

Cureus January 31, 2026 Lukasz Siwek, Marta Nowocien, Barbara Balajewicz et al.

Psilocybin is a psychoactive chemical compound that exerts its effects through the activation of serotonergic receptors. It occurs naturally in mushrooms of the genus Psilocybe. Despite its potential medical applications, this substance is regarded as a drug with no recognized medical use. Depression constitutes a psychiatric disorder of substantial global burden, affecting millions of...

Regarding “The molecular mechanisms through which psilocybin prevents suicide: evidence from network pharmacology and molecular docking analyses”

Translational Psychiatry January 31, 2026 Jesper L. Kristensen

Clinical investigations into the therapeutic actions of psilocybin have been the focus of much attention in recent years as duly cited in the manuscript.The authors of the present manuscript discuss potential targets through which psilocybin may help prevent suicide using computational network pharmacology coupled with molecular docking investigations.Unfortunately, the manuscript contains the...

DOI: 10.1038/s41398-026-03844-7 (opens in new tab) Full text (opens in new tab) Psilocybin Hallucinogen Molecular pharmacology Schizophrenia object-oriented programming +1

Psilocybin-Induced Neuroplasticity and Sustained Antidepressant Effects

Quality in Sport January 31, 2026 Anna Maria Komarczewska, Filip Matusiak, Klaudia Brzoza et al.

Psilocybin-assisted interventions have shown rapid reductions in depressive symptoms in controlled clinical settings, raising questions about biological mechanisms supporting durability beyond the acute drug effect. [5,7] Mechanistic accounts increasingly focus on neuroplasticity as a candidate pathway linking transient serotonergic receptor activation to longer-lasting psychological and...

PSilocybin for psYCHological and existential distress in PALliative care (PSYCHED-PAL): A single arm unblinded clinical trial

Palliative Medicine January 30, 2026 James Downar, Julie Lapenskie, Koby Anderson et al.

Background: Psychological distress is a common problem near the end of life, for which we lack effective, timely and scalable treatments. No previous study has assessed whether microdose psilocybin can improve symptoms in this population. Aim: To determine whether microdose psilocybin is safe, feasible and potentially efficacious in a palliative setting. Design: Open label, single-arm clinical...

DOI: 10.1177/02692163261416269 (opens in new tab) Psilocybin Palliative care Clinical trial Microdose +8

Improving access to psilocybin-assisted therapy: barriers, challenges, and recommendations

Frontiers in Public Health January 29, 2026 Vivian W. L. Tsang, Camille Roney, Pamela Kryskow et al.

Psilocybin-assisted therapy (PAT) is an emerging intervention that combines the administration of psilocybin with structured psychological support to address profound psychological, emotional, and existential distress. Central to this model is the recognition that many forms of suffering-particularly at end of life-are relational in nature and require relational forms of healing. It is our...

DOI: 10.3389/fpubh.2026.1767210 (opens in new tab) Psilocybin Intervention counseling Existentialism Transformative learning +10

Psilocybin and the Evolutionary Significance of Altered Neural States: Interaction-Based Perspectives Beyond Deterrence Models

January 28, 2026 Philip Rebensburg

Psilocybin is a psychoactive tryptamine produced by a phylogenetically discontinuous yet ecologically diverse subset of fungi. Despite decades of chemical, pharmacological, and ethnobiological research, the evolutionary forces driving the emergence and persistence of this compound remain insufficiently explained. Recent hypotheses proposing that psilocybin evolved primarily as a deterrent...

DOI: 10.32942/x2v66q (opens in new tab) Psilocybin Convergent evolution Mechanism biology Relevance law +3

PSILOCYBIN IN PSYCHIATRIC PRACTICE AND PSYCHEDELIC-ASSISTED THERAPY FOR TREATMENT-RESISTANT DEPRESSION

International Journal of Innovative Technologies in Social Science January 28, 2026 Łukasz Deska, Cezary Kosmecki, Dawid Głaz et al.

This manuscript comprehensively reviews psilocybin-assisted therapy for major depressive disorder and treatment-resistant depression. It aims to synthesize current understanding regarding its mechanisms, efficacy, safety, costs, and accessibility, comparing it with conventional antidepressant and ketamine treatments. The methodology involved a narrative synthesis of academic literature, drawing...